Disseminated Herpes Infection Following Talimogene Laherparepvec Administration

JAMA Dermatol. 2022 Apr 1;158(4):456-457. doi: 10.1001/jamadermatol.2022.0020.
No abstract available

MeSH terms

  • Biological Products* / adverse effects
  • Herpesvirus 1, Human*
  • Humans
  • Melanoma* / therapy
  • Oncolytic Virotherapy*
  • Skin Neoplasms* / therapy

Substances

  • Biological Products
  • talimogene laherparepvec